Puma Biotechnology Inc. Stock
Puma Biotechnology Inc. Stock
Puma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Pros and Cons of Puma Biotechnology Inc. in the next few years
Pros
Cons
Performance of Puma Biotechnology Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Puma Biotechnology Inc. | -2.710% | -15.870% | -18.306% | 49.922% | -1.716% | -56.277% | - |
Evolus Inc | -1.650% | 2.586% | 12.264% | 32.222% | 31.492% | 59.732% | - |
Ardelyx Inc. | -1.500% | -0.973% | 16.896% | 117.256% | 23.287% | 25.018% | - |
Salarius Pharmaceuticals Inc. | 0.960% | 1.449% | 0.000% | -63.478% | -24.324% | -98.369% | -99.992% |
News
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement